CellCept
What CellCept is used for
CellCept is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in adult and paediatric (1 to 18 years of age) patients receiving allogeneic renal, cardiac or hepatic transplants.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- CellCept
- Active substance
- mycophenolate mofetil
- Disease area
- Graft Rejection
- Medicine group
- Immunosuppressants
- ATC code
- L04AA06
- Marketing authorisation holder
- Roche Registration GmbH
- Authorised in the EU since
- 1996
Official information
In the USA
In India
- Mycophenolate mofetil: 80 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is CellCept used for?
CellCept is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in adult and paediatric (1 to 18 years of age) patients receiving allogeneic renal, cardiac or hepatic transplants.
What is the active substance in CellCept?
CellCept contains mycophenolate mofetil.
Who makes CellCept?
The EU marketing authorisation holder is Roche Registration GmbH.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU